These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

172 related items for PubMed ID: 6821809

  • 21. Surgical adjuvant therapy for malignant melanoma.
    Pinsky CM, Oettgen HF.
    Surg Clin North Am; 1981 Dec; 61(6):1259-66. PubMed ID: 7031933
    [No Abstract] [Full Text] [Related]

  • 22. Complete remission of metastatic malignant melanoma following immunotherapy with Bacillus Calmette-Guerin (BCG): report of a case.
    Coates AS, Peters M.
    Aust N Z J Surg; 1977 Jun; 47(3):362-5. PubMed ID: 269705
    [Abstract] [Full Text] [Related]

  • 23. Anti-T antibody in malignant melanoma patients. Influence of response and survival following chemotherapy--changes in serum levels following C parvum, BCG immunization.
    Thatcher N, Hashmi K, Chang J, Swindell R, Crowther D.
    Cancer; 1980 Sep 15; 46(6):1378-82. PubMed ID: 7417939
    [Abstract] [Full Text] [Related]

  • 24. Effects of BCG and C. parvum treatment on human melanoma xenografts.
    Garrett AJ, Reeson DE, Osborn TW, Boulger LR.
    Dev Biol Stand; 1980 Sep 15; 38():363-8. PubMed ID: 608525
    [Abstract] [Full Text] [Related]

  • 25. Adjuvant immunostimulation in malignant melanoma with oral Bacille Calmette-Guérin.
    MacGregor AB, Falk RE, Landi S, Ambus U, Samuel ES, Langer B.
    Can J Surg; 1977 Jan 15; 20(1):25-30. PubMed ID: 832200
    [Abstract] [Full Text] [Related]

  • 26. Effects of Corynebacterium parvum and BCG therapy on immune parameters in patients with disseminated melanoma. A sequential study over 28 days. II. Changes in non-specific (NK, K and T cell) lymphocytoxicity and delayed hypersensitivity skin reactions.
    Thatcher N, Swindell R, Crowther D.
    Clin Exp Immunol; 1979 Feb 15; 35(2):171-9. PubMed ID: 312169
    [Abstract] [Full Text] [Related]

  • 27. Controlled study with imidazole carboxamide (DTIC), DTIC + bacillus Calmette-Guérin (BCG), and DTIC + corynebacterium parvum in advanced malignant melanoma. W.H.O. Collaborating Centres for Evaluation of Methods of Diagnosis and Treatment of Melanoma.
    Tumori; 1984 Feb 29; 70(1):41-8. PubMed ID: 6369694
    [Abstract] [Full Text] [Related]

  • 28. Randomized study of Corynebacterium parvum adjuvant therapy following surgery for (stage II) malignant melanoma.
    Thatcher N, Mene A, Banerjee SS, Craig P, Gleave N, Orton C.
    Br J Surg; 1986 Feb 29; 73(2):111-5. PubMed ID: 3512025
    [Abstract] [Full Text] [Related]

  • 29. Adjuvant immunotherapy or chemotherapy for malignant melanoma. Preliminary report of the National Cancer Institute randomized clinical trial.
    Fisher RI, Terry WD, Hodes RJ, Rosenberg SA, Makuch R, Gordon HG, Fisher SG.
    Surg Clin North Am; 1981 Dec 29; 61(6):1267-77. PubMed ID: 7031934
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. A clinical trial of BCG immunotherapy as an adjunct to surgery in the treatment of primary malignant melanoma.
    O'Connor TP, Labandter HP, Hiles RW, Bodenham DC.
    Br J Plast Surg; 1978 Oct 29; 31(4):317-22. PubMed ID: 361132
    [Abstract] [Full Text] [Related]

  • 32. The natural history of resectable metastatic melanoma (Stage IVA melanoma).
    Feun LG, Gutterman J, Burgess MA, Hersh EM, Mavligit G, McBride CM, Benjamin RS, Richman SP, Murphy WK, Bodey GP, Brown BW, Mountain CF, Leavens ME, Freireich EJ.
    Cancer; 1982 Oct 15; 50(8):1656-63. PubMed ID: 7116298
    [Abstract] [Full Text] [Related]

  • 33. Adjuvant treatment in stage I and II malignant melanoma: a randomized trial between chemoimmunotherapy and immunotherapy.
    Castel T, Estapé J, Viñolas N, Mascaró JM, Castro J, Vilalta A, Gratacós R, Daniels M, Palou J, Grau JJ.
    Dermatologica; 1991 Oct 15; 183(1):25-30. PubMed ID: 1769411
    [Abstract] [Full Text] [Related]

  • 34. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
    El-Domeiri AA, Das Gupta TK, Trippon M, Simo C, Sabet TY, Crispen R.
    Surg Gynecol Obstet; 1978 Feb 15; 146(2):230-2. PubMed ID: 622668
    [Abstract] [Full Text] [Related]

  • 35. The serologic response of patients with stage II melanoma to allogeneic melanoma cell vaccines.
    Livingston PO, Kaelin K, Pinsky CM, Oettgen HF, Old LJ.
    Cancer; 1985 Nov 01; 56(9):2194-200. PubMed ID: 4052966
    [Abstract] [Full Text] [Related]

  • 36. Experience with BCG adjuvant immunotherapy in stage II malignant melanoma.
    Deutschmann KE, Peter HH, Schultheis W, Deicher H.
    Tumori; 1977 Nov 01; 63(3):303-7. PubMed ID: 898298
    [Abstract] [Full Text] [Related]

  • 37. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU, Mavligit GM, Reed R, Burgess MA, Gottlieb J, Hersh EM.
    Cancer Treat Rep; 1976 Feb 01; 60(2):177-82. PubMed ID: 769970
    [Abstract] [Full Text] [Related]

  • 38. Chemoimmunotherapy (DTIC and Corynebacterium parvum) as adjuvant treatment in malignant melanoma.
    Karakousis CP, Didolkar MS, Lopez R, Baffi R, Moore R, Holyoke ED.
    Cancer Treat Rep; 1979 Feb 01; 63(11-12):1739-43. PubMed ID: 393377
    [Abstract] [Full Text] [Related]

  • 39. Adjuvant chemoimmunotherapy stage I/II malignant melanoma.
    Knost JA, Reynolds V, Greco FA, Oldham RK.
    J Surg Oncol; 1982 Mar 01; 19(3):165-70. PubMed ID: 7040820
    [No Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.